This is a Level I randomized trial comparing mosaic osteochondral autologous transplantation (OAT) with microfracture for focal femoral condyle cartilage defects. It studied 57 young competitive athletes under 40, following them a mean of 37 months. The question: which technique gives athletes better function and a higher chance of returning to sport?
When counseling a young competitive athlete with a focal femoral condyle defect, this paper gives you concrete numbers to justify OAT over microfracture. The mental model: microfracture produces fibrocartilage that is fine early but fails under athletic load and deteriorates with time. OAT transplants real hyaline cartilage and restores joint congruity that holds up.
Watch the lesion: microfracture failures clustered in defects larger than 2 cm² on the weight-bearing medial condyle, so those are exactly the lesions where you should lean toward OAT. OAT showed no size or location penalty.
Remember the limits. OAT is constrained by donor graft supply, so lesions over 4 cm² were excluded here. Follow-up was only 3 years in a small single-surgeon cohort, and the broader ACI-versus-mosaicplasty literature remains contested (Bentley favored ACI). Use these data for short-to-mid-term counseling, not lifetime durability claims.
This is a Level I randomized trial comparing mosaic osteochondral autologous transplantation (OAT) with microfracture for focal femoral condyle cartilage defects. It studied 57 young competitive athletes under 40, following them a mean of 37 months. The question: which technique gives athletes better function and a higher chance of returning to sport?
When counseling a young competitive athlete with a focal femoral condyle defect, this paper gives you concrete numbers to justify OAT over microfracture. The mental model: microfracture produces fibrocartilage that is fine early but fails under athletic load and deteriorates with time. OAT transplants real hyaline cartilage and restores joint congruity that holds up.
Watch the lesion: microfracture failures clustered in defects larger than 2 cm² on the weight-bearing medial condyle, so those are exactly the lesions where you should lean toward OAT. OAT showed no size or location penalty.
Remember the limits. OAT is constrained by donor graft supply, so lesions over 4 cm² were excluded here. Follow-up was only 3 years in a small single-surgeon cohort, and the broader ACI-versus-mosaicplasty literature remains contested (Bentley favored ACI). Use these data for short-to-mid-term counseling, not lifetime durability claims.